vs

Side-by-side financial comparison of BASSETT FURNITURE INDUSTRIES INC (BSET) and MESA LABORATORIES INC (MLAB). Click either name above to swap in a different company.

BASSETT FURNITURE INDUSTRIES INC is the larger business by last-quarter revenue ($80.1M vs $65.1M, roughly 1.2× MESA LABORATORIES INC). MESA LABORATORIES INC runs the higher net margin — 5.6% vs 1.0%, a 4.6% gap on every dollar of revenue. On growth, BASSETT FURNITURE INDUSTRIES INC posted the faster year-over-year revenue change (5.9% vs 3.6%). MESA LABORATORIES INC produced more free cash flow last quarter ($18.0M vs $-2.6M). Over the past eight quarters, MESA LABORATORIES INC's revenue compounded faster (5.1% CAGR vs -10.7%).

Bassett Furniture Industries, Inc. is a furniture manufacturer and retailer, headquartered in Bassett, Virginia, United States. It was founded in 1902 by John D. Bassett, Charles C. Bassett, Samuel H. Bassett, and Reed L. Stone. Bassett Furniture is one of the oldest furniture manufacturers in Virginia. The company began when the founders, operating a family sawmill in the foothills of the Blue Ridge Mountains, decided to use surplus lumber to produce bedroom furniture. According to oral hist...

Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.

BSET vs MLAB — Head-to-Head

Bigger by revenue
BSET
BSET
1.2× larger
BSET
$80.1M
$65.1M
MLAB
Growing faster (revenue YoY)
BSET
BSET
+2.3% gap
BSET
5.9%
3.6%
MLAB
Higher net margin
MLAB
MLAB
4.6% more per $
MLAB
5.6%
1.0%
BSET
More free cash flow
MLAB
MLAB
$20.7M more FCF
MLAB
$18.0M
$-2.6M
BSET
Faster 2-yr revenue CAGR
MLAB
MLAB
Annualised
MLAB
5.1%
-10.7%
BSET

Income Statement — Q3 FY2025 vs Q3 FY2026

Metric
BSET
BSET
MLAB
MLAB
Revenue
$80.1M
$65.1M
Net Profit
$801.0K
$3.6M
Gross Margin
56.2%
64.2%
Operating Margin
0.7%
12.2%
Net Margin
1.0%
5.6%
Revenue YoY
5.9%
3.6%
Net Profit YoY
117.8%
316.6%
EPS (diluted)
$0.09
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BSET
BSET
MLAB
MLAB
Q4 25
$65.1M
Q3 25
$80.1M
$60.7M
Q2 25
$84.3M
$59.5M
Q1 25
$62.1M
Q4 24
$92.1M
$62.8M
Q3 24
$75.6M
$57.8M
Q2 24
$58.2M
Q1 24
$86.6M
$58.9M
Net Profit
BSET
BSET
MLAB
MLAB
Q4 25
$3.6M
Q3 25
$801.0K
$2.5M
Q2 25
$1.9M
$4.7M
Q1 25
$-7.1M
Q4 24
$508.0K
$-1.7M
Q3 24
$-4.5M
$3.4M
Q2 24
$3.4M
Q1 24
$-1.2M
$-254.6M
Gross Margin
BSET
BSET
MLAB
MLAB
Q4 25
64.2%
Q3 25
56.2%
61.5%
Q2 25
55.6%
62.0%
Q1 25
61.8%
Q4 24
55.7%
63.3%
Q3 24
53.0%
61.3%
Q2 24
64.0%
Q1 24
55.3%
62.1%
Operating Margin
BSET
BSET
MLAB
MLAB
Q4 25
12.2%
Q3 25
0.7%
7.8%
Q2 25
3.0%
5.1%
Q1 25
2.4%
Q4 24
-1.3%
9.2%
Q3 24
-8.4%
6.1%
Q2 24
9.6%
Q1 24
-2.7%
-460.6%
Net Margin
BSET
BSET
MLAB
MLAB
Q4 25
5.6%
Q3 25
1.0%
4.1%
Q2 25
2.3%
8.0%
Q1 25
-11.4%
Q4 24
0.6%
-2.7%
Q3 24
-6.0%
5.9%
Q2 24
5.8%
Q1 24
-1.4%
-432.2%
EPS (diluted)
BSET
BSET
MLAB
MLAB
Q4 25
$0.65
Q3 25
$0.09
$0.45
Q2 25
$0.22
$0.85
Q1 25
$-1.30
Q4 24
$0.07
$-0.31
Q3 24
$-0.52
$0.63
Q2 24
$0.62
Q1 24
$-0.14
$-47.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BSET
BSET
MLAB
MLAB
Cash + ST InvestmentsLiquidity on hand
$54.6M
$29.0M
Total DebtLower is stronger
$68.4M
Stockholders' EquityBook value
$165.7M
$186.7M
Total Assets
$324.2M
$434.8M
Debt / EquityLower = less leverage
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BSET
BSET
MLAB
MLAB
Q4 25
$29.0M
Q3 25
$54.6M
$20.4M
Q2 25
$59.8M
$21.3M
Q1 25
$27.3M
Q4 24
$59.9M
$27.3M
Q3 24
$56.2M
$24.3M
Q2 24
$28.5M
Q1 24
$58.4M
$28.2M
Total Debt
BSET
BSET
MLAB
MLAB
Q4 25
$68.4M
Q3 25
$69.4M
Q2 25
$70.3M
Q1 25
$71.3M
Q4 24
$72.2M
Q3 24
$73.1M
Q2 24
$74.1M
Q1 24
Stockholders' Equity
BSET
BSET
MLAB
MLAB
Q4 25
$186.7M
Q3 25
$165.7M
$178.5M
Q2 25
$166.8M
$172.5M
Q1 25
$159.8M
Q4 24
$167.3M
$155.2M
Q3 24
$165.0M
$161.5M
Q2 24
$150.7M
Q1 24
$180.6M
$145.4M
Total Assets
BSET
BSET
MLAB
MLAB
Q4 25
$434.8M
Q3 25
$324.2M
$430.4M
Q2 25
$331.3M
$435.7M
Q1 25
$433.3M
Q4 24
$341.2M
$433.3M
Q3 24
$335.9M
$454.1M
Q2 24
$440.4M
Q1 24
$361.4M
$446.8M
Debt / Equity
BSET
BSET
MLAB
MLAB
Q4 25
0.37×
Q3 25
0.39×
Q2 25
0.41×
Q1 25
0.45×
Q4 24
0.47×
Q3 24
0.45×
Q2 24
0.49×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BSET
BSET
MLAB
MLAB
Operating Cash FlowLast quarter
$-1.2M
$18.8M
Free Cash FlowOCF − Capex
$-2.6M
$18.0M
FCF MarginFCF / Revenue
-3.3%
27.7%
Capex IntensityCapex / Revenue
1.8%
1.1%
Cash ConversionOCF / Net Profit
-1.47×
5.17×
TTM Free Cash FlowTrailing 4 quarters
$37.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BSET
BSET
MLAB
MLAB
Q4 25
$18.8M
Q3 25
$-1.2M
$8.2M
Q2 25
$1.9M
Q1 25
$12.7M
Q4 24
$18.1M
Q3 24
$5.4M
$5.3M
Q2 24
$10.7M
Q1 24
$-7.7M
$12.9M
Free Cash Flow
BSET
BSET
MLAB
MLAB
Q4 25
$18.0M
Q3 25
$-2.6M
$7.1M
Q2 25
$884.0K
Q1 25
$11.9M
Q4 24
$17.3M
Q3 24
$2.8M
$3.5M
Q2 24
$9.9M
Q1 24
$-9.8M
$12.3M
FCF Margin
BSET
BSET
MLAB
MLAB
Q4 25
27.7%
Q3 25
-3.3%
11.7%
Q2 25
1.5%
Q1 25
19.2%
Q4 24
27.6%
Q3 24
3.7%
6.0%
Q2 24
16.9%
Q1 24
-11.3%
21.0%
Capex Intensity
BSET
BSET
MLAB
MLAB
Q4 25
1.1%
Q3 25
1.8%
1.8%
Q2 25
1.7%
Q1 25
1.2%
Q4 24
1.3%
Q3 24
3.5%
3.1%
Q2 24
1.5%
Q1 24
2.4%
0.9%
Cash Conversion
BSET
BSET
MLAB
MLAB
Q4 25
5.17×
Q3 25
-1.47×
3.32×
Q2 25
0.40×
Q1 25
Q4 24
Q3 24
1.54×
Q2 24
3.17×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BSET
BSET

Retail Segment$51.9M65%
Bassett Custom Upholstery$18.7M23%
Accessories Mattresses And Other$6.9M9%
Bassett Custom Wood$2.7M3%

MLAB
MLAB

Sterilization And Disinfection Control$24.9M38%
Biopharmaceutical Development$14.4M22%
Other$14.1M22%
Clinical Genomics$11.8M18%

Related Comparisons